skip to navigation skip to content
Search

Nektarios (Aris) Oraiopoulos

Financial Times: FT business books – March edition

“From Breakthrough to Blockbuster”, a book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, was included in the March list of top business books of the month by the Financial Times, which says the book “tells the…

Read more

India Education Diary: New book highlights how small biotech companies are outperforming big pharma

From Breakthrough to Blockbuster: The Business of Biotechnology, a new book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, shows how small, inexperienced entrepreneurial companies making up the biotech industry have created more life-changing medicines than all…

Read more

From Breakthrough to Blockbuster

New book co-authored by Nektarios Oraiopoulos of Cambridge Judge Business School charts the rise of entrepreneurial biotech firms. Dr Nektarios Oraiopoulos From Breakthrough to Blockbuster: The Business of Biotechnology, published today, shows how the small, inexperienced entrepreneurial companies making up…

Read more

Small, inexperienced entrepreneurial companies making up the biotech industry have created more life-changing medicines than all of the large pharmaceutical companies combined.

Executive Courses: Executive education courses in data analytics

Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. “Businesses and their leaders can use data to understand better, in an un-biased way, how they can create value for their customers,”…

Read more

Forbes India: How drug companies can increase their R&D effectiveness

A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…

Read more

Pharma shift

The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…

Read more

2020 webinars whats next 883x432 1

Biotech vs big pharma

Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…

Read more

2020 brainfood oraiopoulos derisking drug innovation 1998x642 1

Manhattan Project?

A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…

Read more

2020 brainfood manhattan project 883x432 1

Fast Company: How open-source medicine could prepare us for the next pandemic

A study on drug repurposing co-authored by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. The study found that “about 31 per cent of drugs approved by the FDA had…

Read more

Pharma Voice: New pipeline pathways

Repurposing existing drugs could reduce cost and time when developing new medicine, but it’s not a straightforward approach. According to a study by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge, only two per cent of new…

Read more

Archives